HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration has approved DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) as the first-ever treatment for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results